NYSE:ALT - Altimmune Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.43 -0.01 (-0.41 %) (As of 05/24/2019 06:54 AM ET)Previous Close$2.44Today's Range$2.36 - $2.4752-Week Range$1.70 - $36.25Volume144,200 shsAverage Volume1.18 million shsMarket Capitalization$22.06 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland. Receive ALT News and Ratings via Email Sign-up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSE:ALT Previous Symbol CUSIPN/A CIK1326190 Webhttp://www.altimmune.com/ PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares9,078,000Market Cap$22.06 million Next Earnings Date8/13/2019 (Estimated) OptionableOptionable Altimmune (NYSE:ALT) Frequently Asked Questions What is Altimmune's stock symbol? Altimmune trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALT." When is Altimmune's next earnings date? Altimmune is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Altimmune. What is the consensus analysts' recommendation for Altimmune? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Altimmune. Has Altimmune been receiving favorable news coverage? News coverage about ALT stock has been trending negative on Friday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Altimmune earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the immediate future. Who are some of Altimmune's key competitors? Some companies that are related to Altimmune include Acasti Pharma (ACST), Botanix Pharmaceuticals (BOT), Antibe Therapeutics (ATE), Tiziana Life Sciences (TILS), Mereo BioPharma Group (MPH), Bionomics (BNO), Noxopharm (NOX), OptiBiotix Health (OPTI), Orgenesis (ORGS), Promis Neurosciences (PMN), Tissue Regenix Group (TRX), 4d Pharma (DDDD), IntelGenx Technologies (IGX), Pediapharm (PDP) and Verona Pharma (VRP). What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Cara Therapeutics (CARA), Cronos Group (CRON), IQIYI (IQ), Novavax (NVAX), Aurora Cannabis (ACB), Canopy Growth (CGC), NIO (NIO), Arena Pharmaceuticals (ARNA), Corbus Pharmaceuticals (CRBP) and ImmunoGen (IMGN). Who are Altimmune's key executives? Altimmune's management team includes the folowing people: Mr. William J. Enright, Pres, CEO & Director (Age 55)Dr. M. Scot Roberts Ph.D., Chief Scientific Officer (Age 59)Dr. Sybil Tasker, Chief Medical Officer (Age 55)Mr. Will Brown, Acting CFO & Principal Accounting Officer (Age 36)Mr. Bertrand Georges Ph.D., Chief Technology Officer How do I buy shares of Altimmune? Shares of ALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Altimmune's stock price today? One share of ALT stock can currently be purchased for approximately $2.43. How big of a company is Altimmune? Altimmune has a market capitalization of $22.06 million. What is Altimmune's official website? The official website for Altimmune is http://www.altimmune.com/. MarketBeat Community Rating for Altimmune (NYSE ALT)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 67 (Vote Outperform)Underperform Votes: 87 (Vote Underperform)Total Votes: 154MarketBeat's community ratings are surveys of what our community members think about Altimmune and other stocks. Vote "Outperform" if you believe ALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Earnings Per Share (EPS) Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.